Healthcare · Vaccine antigens production

Vaccine antigens production in USA in 2026

In 2026, vaccine antigen production in the USA stood at 500 million doses, placing the country 2nd among 197 nations. The zero figure reflects that the data covers only finished antigens for export, while American companies (Pfizer, Moderna, Merck) focus on developing and manufacturing final vaccines rather than intermediate substances. Key facilities are located in Massachusetts, Missouri, and Pennsylvania, where cutting-edge mRNA and viral platforms are created.

Data for 2026 · unit: million doses
Position

USA world ranking

#2 / 197

Country position on the scale from last to first place for this indicator.

US
#2
#197#1
Trend

Change over time

Change in indicator over the available period.

1
1950
50 M
1990
80 M
2000
100 M
2010
150 M
2020
500
2025
500
2026

Values — million doses

Related questions

People also search for

Other pages of the reference by this indicator.

Summary

Frequently asked questions

Vaccine antigens production in USA — how much?
Based on 2026 data — 500 million doses. This is rank #2 out of 197 countries.
What is USA's rank by Vaccine antigens production?
USA ranks #2 out of 197 countries in the world ranking by «Vaccine antigens production».
How has Vaccine antigens production changed in USA?
Over the available period the indicator changed from 1 to 500 million doses.